|
 |
Company Study of Jiangsu Hengrui Medicine
|
Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the company's profit. In the consecutive seven years since it went public, the profit of main business has been increasing by 28.7% year-on-year, and the net profit has been enjoying a CAGR of 22%. In addition, the company successively purchased Chengdu Hengrui Pharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd., and the latter became a new drug R&D center afterward.
The two R&D centers of the company are respectively located in Lianyungang and Shanghai, both having its own work division and pipelining production ability. Shanghai R&D center is mainly in charge of the prophase research of new drugs.
In the year of 2006, the company's sales revenue from anti-tumor drugs reached RMB 856 million, up 632% from a year earlier. New drugs were successively launched into the market and thus the era of oxaliplatin and docetaxel came up. The sales revenue of Narcotic analgesic drugs mainly including Levobupivacaine and Atracurium Besilate amounted to RMB 128 million, rising 472% year-on-year. And anti-infectious drugs mainly including clarithromycin realized sales revenue of RMB 247 million, a rise of 193% over 2005.
In the years of 2004-2006, the capital invested into R&D was RMB 80 million, 100 million and 120 million respectively, accounting for 7.01%, 8.48% and 8.43% of the annual revenue from main business separately. Five kinds of the company's new drugs are in clinic trial or in planned clinic trial currently.
It is forecasted that in the year of 2007, the sales revenue of Jiangsu Hengrui Medicine Co., Ltd. will reach RMB 1.71 billion from the main business, up by 20% year-on-year; the net profit will amount to RMB 301 million, up 45.4% from a year earlier. In 2008, the sales revenue from main business and the net profit will be RMB 2.03 billion and RMB 450 million respectively with a year-on-year growth of 18.7% and 49.5% separately.
Structure of Main Business of Hengrui Medicine Co., Ltd
Historical Statistics of the Hengrui's Operation (Unit: RMB Million)
1 Retrospect of the Hengrui's operation
1.1 Share rights alternation of listed companies
1.2 Statistics of profit from main business
2 Redefinition of new drugs
2.1 China's backward ability in developing new drugs
2.2 Leading R&D ability of the industry
2.3 Influence of the redefinition for new drugs
3 Development strategies
3.1 Patent-drug strategy
3.2 Internationalization strategy
4 Analysis on new products
4.1 Imrecoxib
4.2 Cartrofloxacin
4.3 Apatinib
4.4 Ambroxol
5 Profit forecast
5.1 Anti-tumor drugs
5.2 Drugs for operation
5.3 Anti-infectious drugs
5.4 Cardiovascular drugs
5.5 Forecast on the sales of other drugs
Alternation of equity structure during the process of private economy
Structure of Hengrui's revenue from main business
Product structure of Hengrui
Historical statistics of Hengrui's operation
Evolvement in developing new drugs
Forecasted sales from the company’s main anti-tumor drugs
Forecasted sales from drugs for operation
Forecasted sales from anti-infectious drugs
Forecasted sales from cardiovascular drugs
Forecasted sales from other drugs
Forecast on Hengrui's financial indicators
Forecast on Hengrui's profit
China Animal Vaccine Industry Report, 2009-2010 China’s animal vaccine market has grown up steadily despite all the twists and turns in the livestock and poultry breeding market over the past four years. In 2009, the market scale reached around RMB... Global and China Medical Devices Industry Report, 2009 The development of medical devices industry differs afar in developed countries and developing countries. In emerging markets like China and India, it is the economic growth that drives the expansion ... China Medical Sales and Medical Device Market Report, 2008 In the recent years, Chinese medical device market developed rapidly. During Jan to Nov 2008, 915 medical device companies were together realized a sales revenue of CNY 63.6 billion, accounting for 9.... China Diagnostic Reagent Market Report, 2007-2009 China's diagnostic reagent industry had lagged behind other countries for a long time. Since 1980s, China's reagent for clinical diagnosis has started entering the industrialization process, following... China Portable Medical Devices Report, 2007-2008 In 2007, the market scale of portable medical devices in China was CNY 24.56 billion, up by 16.5% year on year, which was mainly contributed by the purchase growth from large hospitals.
China ... Investment Report of China Medical Industry, 2000-2008 China is the largest country in the world in terms of population. Its population of 1.3 billion people provides a huge market for the development of China's medical service industry. The existing medi... Company Study of Huadong Medicine Huadong Medicine Co., Ltd. was founded in March, 1993, based on the medicine distribution network in Hanzhou, capital of Zhejiang province, after a government-oriented restructuring. On December 22, 1... China Medical Device Industry and Listed Company Report, 2008 China is a large medical apparatus and instruments producer in both Asia and the world. China, as one of the top ten emerging markets in the world's medical apparatus and instruments industry, had a m... Political Influence Study of China Medical Industry, 2007 China started the cut down the medicine price dramatically for the 21st time in Jan, 2007, and the management board also stated that it will continue to squeeze the medicine price foams for many times... China Medical Devices Market Report, 2007 Presently, the global sales revenue of medical device amounted to about USD 250 billion. Developed countries and regions take the majority of market shares, among which America takes 40%, Europe 30%, ... Company Study of Jiangsu Hengrui Medicine Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the company's profit. In the ... China Medicated Health Product Industry Report, 2007 It's estimated that in the forthcoming couple of years, the growth rate of the sales income of the medical industry will remain at 15-17%. In the long term, thanks to the highest growth speed, China's... China Medical Industry Report, 2007 In the first quarter of 2007, the main business income of the whole medical manufacturing industry increased steadily, and growth margin of total profit exceeded 10% of the main business income. In ad... China Medical Sales Channel Report, 2006-2007 In the first three quarters of 2006, the total sales value of top seven medicine merchandises in China amounted to RMB 211.838 billion, up by 8.07% year-on-year, among which, the total sales value of ... China Medical Device Industry Report, 2005-2006 By the end of Dec 2005, the total assets of China medical device industry has reached RMB33.856 billion, in Q4 2005, the sales revenue of China medical device industry was RMB10.429 billion, increased... China Medical Devices Market Report, 2005 According to HIMA forecast, global medical instrument sales will reach $260 billion in 2006. The US medical instrument growth rate maintained at 9 percent.
According to the forecast of the 10th five... China Woundcare Products: Supplier Capability Report, 2005 China is poised to become one of the world’s largest exporters of woundcare products. Their market share is expected to increase further as suppliers boost production, gain CE marking and FDA approval... China Medical Imaging: Supplier Capability Report, 2005 China is poised to be a large exporter of medical imaging equipment in the world. Their market share is expected to increase further as suppliers boost production, gain CE marking and FDA approvals an...
|